Clinical Trial Update: SCIO-469: Open-Label Study for Patients With Myelodysplastic Syndromes. [Phase 2]

View source ↗

Summary

A Phase 2 open-label study of SCIO-469 in patients with myelodysplastic syndromes has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• SCIO-469

Snippet

Sponsor: Scios, Inc. | Conditions: Bone Marrow Diseases, Myelodysplastic Syndromes | Phase 2 | Status: COMPLETED